- The partnership will leverage Tessa Therapeutics' global operational capabilities and cell therapy platform technologies to target prevalent cancers in China - The joint venture will be the sole licensee of Tessa Therapeutics' cell therapies for research, development and commercialization in China Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of autologous and allogeneic therapies to treat cancer, announced today that it will establish a joint venture with China-Singapore Guangzhou Knowledge City (CSGKC). The joint venture will be the sole licensee of Tessa's cell therapies for research, clinical development and commercialization in China. Tessa and CSGKC will invest a combined total of US$120 million in the joint venture – CSGKC will contribute US$80 million and Tessa will provide US$40 million – in two stages. In the first stage, CSGKC will contribute US$40 million for 13 percent stake in the joint venture, while Tessa will contribute US$20 million and its technology license rights for China. Tessa will hold the remaining 87 percent stake in the joint venture. "China is an important market in our goal to develop innovative cell therapies and make them widely accessible for cancer patients all over the world," said Mr. Andrew Khoo, Tessa Therapeutics CEO and Co-Founder. "The joint venture is an important milestone in Tessa's China strategy and will draw from Tessa's international clinical execution capability and cell therapy platform technologies. I firmly believe that having China as a core part of Tessa's global clinical development strategy will accelerate our cell therapies to market." The joint venture's immediate strategic priorities will focus on conducting clinical trials in China for Tessa's cell therapies, which target prevalent cancers in the country for patients with hematological malignancies and solid tumors. This will be done by building up robust operational capabilities and adding leading clinical trial sites in China into Tessa's global clinical trial network. About China-Singapore Guangzhou Knowledge City China-Singapore Guangzhou Knowledge City (CSGKC) formerly known as the Sino-Singapore Guangzhou Knowledge City (SSGKC) is a greenfield master development by Sino-Singapore Guangzhou Knowledge City Investment and Development Co., Ltd, a joint venture company established by Ascendas-Singbridge and Guangzhou Development District (GDD). Situated approximately 35 km northeast of Guangzhou city centre and 25 km from Guangzhou Baiyun International Airport, it is strategically located in the core area of the Greater Bay Area, a key integrated economic hub which is slated to become the world largest bay economy. Envisioned as a model and catalyst for Guangdong's economic transformation, the 123 sq km CSGKC is positioned as a unique, vibrant and sustainable city highly attractive to both talents and knowledge-based industries. Since its inception in 2010, CSGKC has achieved significant progress. Following the completion of basic infrastructure works in the 6.27 sqkm Start-Up Area (SUA) and the opening of two new subway lines by end of 2018, accessibility and connectivity in the area have improved significantly. Furthermore, CSGKC has also seen the completion of phase 1 OneHub GKC, an integrated business park development comprising business and commercial space, high-end residential and lifestyle amenities. Plans for the next phase of development has kickstarted with joint exploration for the development of the 2 sqkm Sino-Singapore International Technology Innovation Cooperation Demonstration Area (Demonstration Area) within CSGKC. The importance of CSGKC continues to grow with the signing of a Framework Agreement between Chinese and Singapore government on 12th November 2018 to elevate the project to a State-Level Bilateral Cooperation Project, making it the first private sector-led project to receive state level elevation. Building upon its new status as well as leveraging on the growth of the Greater Bay Area, CSGKC is well positioned to become a dynamic, high value urban centre with opportunities for local and international enterprises. For more information on CSGKC, please visit www.ssgkc.com. About Tessa Therapeutics Tessa Therapeutics is a clinical-stage cell therapy company focused on the development of autologous and off-the-shelf, allogeneic therapies targeting a wide range of cancers. Tessa's Virus-Specific T cell (VST) platform harnesses the body's potent anti-viral immune response and has shown early efficacy and a strong safety profile in the treatment of solid tumors. Tessa is building a portfolio of innovative, next-generation therapies by combining VSTs with other immuno-oncology approaches. This portfolio includes a rapidly growing pipeline of clinical and pre-clinical autologous programs that target a wide range of cancers, including nasopharyngeal carcinoma, cervical cancer, oropharyngeal cancer, lung cancer, breast cancer, bladder cancer, as well as head and neck cancer. In addition, Tessa is leveraging its platform to develop allogeneic therapies to address Epstein-Barr virus-associated lymphomas and solid tumors. Tessa has built up robust operational and supply chain capabilities to successfully deliver T cell therapy treatments to a large patient pool worldwide. Together with the Company's academic, clinical, and commercial research partners, Tessa has created a fully-integrated approach to the treatment of cancer with immunotherapy. For more information on Tessa, please visit www.tessatherapeutics.com. Tessa Therapeutics Media Contacts Gladys Wong gladyswong@tessatherapeutics.com +65 6384 0755 Brunswick Group Will Carnwath, Ben Fry TessaTherapeutics@brunswickgroup.com +65 6426 8188 Source: Tessa Therapeutics